Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic
activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3
for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Kalyan Nadiminti, MD
All
18 Years and over
Phase 1
This study is NOT accepting healthy volunteers
NCT05735184
Show full eligibility criteria
Hide eligibility criteria
Key
Inclusion Criteria:
• Patients must have a documented NPM1 mutation or KMT2A rearrangement and have either
newly diagnosed or relapsed/refractory AML
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Adequate liver, renal, and cardiac function according to protocol defined criteria
• A female of childbearing potential must agree to use adequate contraception from the
time of screening through 180 days following the last dose of study intervention. A
male of childbearing potential must agree to use abstinence or adequate contraception
from the time of screening through 90 days following the last dose of study
intervention
Key
Exclusion Criteria:
• Diagnosis of either acute promyelocytic leukemia or blast chronic myelomonocytic
leukemia
• Known history of BCR-ABL alteration
• Advanced malignant hepatic tumor [for patients receiving ven/aza combination]
• Administration of live attenuated vaccines within 14 days prior to, during, or after
treatment until B-cell recovery
• Active central nervous system (CNS) involvement by AML.
• Clinical signs/symptoms of leukostasis or WBC > 25,000 / microliter. Hydroxyurea
and/or leukapheresis are permitted to meet this criterion
• Not recovered to Grade ≤1 (NCI-CTCAE v5.0) from all nonhematological toxicities except
for alopecia
• Known clinically active human immunodeficiency virus, active hepatitis B or active
hepatitis C infection
• For newly diagnosed cohorts: received prior chemotherapy for leukemia, except
hydroxyurea and/or leukapheresis to control leukocytosis, prior treatment with
all-transretinoic acid for initially suspected acute promyelocytic leukemia, or
non-HMA therapy for prior myelodysplastic syndrome
• For relapsed/refractory cohorts: received chemotherapy, immunotherapy, radiotherapy,
or any ancillary therapy that is considered to be investigational < 14 days prior to
the first dose of ziftomenib or within 5 drug half-lives prior to the first dose of
study drug
• Uncontrolled intercurrent illness including, but not limited to, cardiac illness as
defined in the protocol
• Mean corrected QT interval corrected for heart rate by Fredericia's formula (QTcF)
>480 ms on triplicate ECGs
• Uncontrolled infection
• Women who are pregnant or lactating
• An active malignancy and currently receiving chemotherapy for that malignancy or
disease that is uncontrolled/progressing
AcuteMyeloidLeukemia, Mixed Lineage AcuteLeukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype AcuteLeukemia, Refractory AML, AML With Mutated NPM1, AcuteMyeloidLeukemia Recurrent, AcuteMyeloidLeukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Myeloid and Monocytic Leukemia, Leukemia
*Note: Email is generally not a secure way to communicate sensitive or health-related information as there are many ways for unauthorized users to access email. You should avoid sending sensitive, detailed personal information by email.